VENUSREM
Venus Remedies Limited (VENUSREM) Stock Analysis
Venus Remedies Limited develops and markets injectable antibiotics, oncology, and critical-care medicines in India and abroad. It operates formulation plants with focus on hospital injectables and licensed products. The company exports to regulated markets from Punjab. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,719.50
-0.08% 1W | +264.90% 52W
Market Cap
2.3k CR
P/E Ratio
22.4
52W High
₹2044.3
52W Low
₹424
Div. Yield
0.59%
Beta
0.2
50 DMA
₹1414.6
200 DMA
₹893.1
Profit Margin
13.4%
Inst. Own.
1.2%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating Profit | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 11% | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other Income | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 77% | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net Profit | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS in Rs | 0.88 | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 645 | 766 | 811 |
| Expenses | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 619 | 645 |
| Operating Profit | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 69 | 147 | 166 |
| OPM % | 20% | 20% | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 11% | 19% | 20% |
| Other Income | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 26 | 13 | 12 |
| Interest | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 | 26 |
| Profit before tax | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 | 152 |
| Tax % | -95% | 52% | -21% | 11% | -4% | 24% | -27% | -12% | 30% | 36% | 37% | 23% | |
| Net Profit | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS in Rs | 4.51 | 1.49 | -13.84 | -24.87 | -23.15 | -8.10 | 50.05 | 30.46 | 19.88 | 21.31 | 33.90 | 76.90 | 86.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 12.0% | 7.0% | 7.0% |
| Profit CAGR | 53.0% | 20.0% | 50.0% |
Shareholding Pattern
Promoters41.76%
FIIs1.86%
DIIs0.75%
Public55.62%
Promoters41.76%
FIIs2.25%
DIIs1.03%
Public54.95%
Promoters41.76%
FIIs2.80%
DIIs1.20%
Public54.24%
Promoters41.76%
FIIs2.92%
DIIs0.89%
Public54.44%
Promoters41.76%
FIIs3.14%
DIIs0.74%
Public54.37%
Promoters41.76%
FIIs1.00%
Public57.26%
Promoters41.76%
FIIs1.48%
Public56.76%
Promoters41.76%
FIIs1.34%
Public56.90%
Promoters41.76%
FIIs2.80%
DIIs1.20%
Public54.24%
Promoters41.76%
FIIs3.14%
DIIs0.74%
Public54.37%
VENUSREM
Holdings Analysis
Key strengths & risk signals
69
Overall
66
Fundamental
72
Technical
Risks (3)
TOO MUCH PUBLIC HOLDING! 57.26% public ownership - higher volatility risk.
RECOVERY MODE! Current price (1610.1) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 10.4% (1 week), 2.4% (1 month), 6.4% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.32 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (1653.1) is above 200-day average (1238.7) - positive signal.
EXCELLENT YEAR! Stock gained 284.3% in the last year.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Fundamental & Technical Analysis
69Overall
66Fundamental
72Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 9.9% (MODERATE, 8/15). Profit CAGR: 57.0% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 14.3% profit margin - acceptable profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.32 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.59% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 57.26% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1653.1) is above 200-day average (1238.7) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1610.1) above 200-day but below 50-day.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 284.3% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 33,129 vs down days: 26,741. Ratio: 1.24x
RSI
3/5
NEUTRAL! RSI at 44.3 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 73.1% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 10.4% (1 week), 2.4% (1 month), 6.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| INDOCO | ₹230.70 | 699.1 | 0.3% | 3.0% | – | -14.2% | 54 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| WINDLAS | ₹949.20 | 30.4 | 7.1% | 20.7% | 16.0% | +11.7% | 75 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| BETA | ₹1,950.20 | 28.7 | 11.1% | 19.2% | 10.5% | +13.7% | 67 | APPROACHING SUPPORT | +35.0% | +75.6% | +25.2% | +33.5% |
| HESTERBIO | ₹2,058.70 | 12.8 | 41.6% | 7.7% | 27.8% | +24.4% | 76 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
Data from TradeAlone · Updated daily
No news tagged for VENUSREM yet.
